What is the LEADER study?

The LEADER study was started in 2010 and investigated a once-daily diabetes treatment developed by Novo Nordisk, and the effect it has on heart disease in people with type 2 diabetes. LEADER finished in February 2016 and reported the main results in June 2016.

Long-term studies such as LEADER are also known as outcomes studies, and have been cornerstones for medical advancements for many years.

LEADER is sponsored by Novo Nordisk.


Who took part in the LEADER study?

People with type 2 diabetes and at high risk for heart disease were invited to take part in LEADER. In total 9,340 participants were included in the study, across 410 LEADER trial sites in 32 different countries.

Global LEADER overview :


Click on the map to know number of randomized participants and trial sites in participating countries.